Oxbryta Product Registry (Sickle Cell Disease) - Clinical Trial
What is the Purpose of this Study?
We are doing this study to learn more about the effects of the prescription drug Oxbryta (voxelotor) on sickle cell disease (SCD) when it is prescribed to patients. We want to keep track of the health of people with SCD who take this drug as part of their normal care.
Sickle Cell Disease
Who Can Participate in the Study?
Adults and children who:
- Are diagnosed with SCD
- Started taking Oxbryta within the past 6 months or plan to begin taking Oxbryta in the future
For more information about this study, please contact the study team at stephanie.padrick@duke.edu.
What is Involved?
If you choose to join this study, you will:
- Fill out surveys about every 6 months during your regularly scheduled hematology visits
- Give us permission to collect information from your medical records for research
Participation in this study will last up to 5 years. We will collect information related to your health for one year or less before you begin taking Oxbryta if you do not use it when you join the study, and we will collect information related to your health for up to 5 years while you are taking Oxbryta.
Study Details
